A Phase 1, Open-label, Dose Escalation Study of MGA271 in Pediatric Patients With B7-H3-Expressing Relapsed or Refractory Solid Tumors
Latest Information Update: 09 Feb 2022
Price :
$35 *
At a glance
- Drugs Enoblituzumab (Primary)
- Indications Ewing's sarcoma; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
- Focus Adverse reactions
- Sponsors MacroGenics
- 30 May 2019 Status changed from active, no longer recruiting to completed.
- 28 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology